Clinical Report: Empagliflozin Improves Cardiac Function in Obese Diabetic Mice
Overview
Empagliflozin treatment in a mouse model of HFpEF improved cardiac function and modified gene expression related to cardiomyocyte electrophysiology and excitation-contraction coupling. These findings suggest potential mechanisms for the cardiovascular benefits of empagliflozin beyond glycemic control.
Background
Heart failure with preserved ejection fraction (HFpEF) represents a significant clinical challenge, accounting for over half of all heart failure cases with limited effective treatments. The use of SGLT2 inhibitors like empagliflozin has emerged as a promising therapeutic strategy, demonstrating cardiovascular benefits that extend beyond their antidiabetic effects. Understanding the mechanisms by which empagliflozin exerts these benefits is crucial for optimizing treatment in patients with HFpEF.
Data Highlights
Empagliflozin treatment in db/db + Aldo mice demonstrated improvements in cardiac function and gene expression related to electrophysiology and excitation-contraction coupling.
Key Findings
Empagliflozin improved diastolic function in HFpEF mouse models.
Treatment reversed proarrhythmogenic action potential changes in cardiomyocytes.
Empagliflozin reduced levels of reactive oxygen species and O-GlcNAc modified proteins.
Chronic treatment restored cardiomyocyte electrophysiology and excitation-contraction coupling mechanisms.
Empagliflozin's effects were observed even in the absence of the drug, indicating lasting benefits.
Clinical Implications
The findings support the use of empagliflozin as a therapeutic option for patients with HFpEF, highlighting its potential to improve cardiac function and modify underlying pathophysiological mechanisms. Clinicians should consider the broader cardiovascular benefits of SGLT2 inhibitors in managing heart failure, particularly in patients with concurrent diabetes.
Conclusion
Empagliflozin demonstrates significant potential in improving cardiac function and modifying gene expression in HFpEF models, warranting further investigation in clinical settings. These results reinforce the importance of SGLT2 inhibitors in the management of heart failure.
by Juliana Mira Hernandez, Logan R. J. Bailey, Victoria R. Salemme, Christopher Y. Ko, Erin Y. Shen, Megan Ngim, Duong T. Hoang, Melissa Corea, Julie Bossuyt, Jennifer M. Davis, Donald M. Bers, Bence Hegyi
